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a  b  s  t  r  a  c  t
In breast  cancer  the  human  epidermal  growth  factor  receptor  2  (HER2)  is an  important  target  for  a
number  of different  HER2  inhibitors.  Different  slide-based  assays  are  available  for assessment  of  treat-
ment  eligibility,  which  include  ﬂuorescence  in  situ  hybridization  (FISH)  or other  in situ  hybridization
(ISH)  methods  for assessment  of  the HER2  gene  status.  Here  we  report  a summary  of the  validation
data  on  HER2  IQFISH  pharmDxTM (Dako  Omnis),  a  newly  developed  assay  for  the  automated  staining
platform  Dako  Omnis.  The  assay  uses  a non-toxic  buffer  that  signiﬁcantly  reduces  the  hybridization
time,  which  results  in  a total  turnaround  time  of  3½  to  4 h from  deparafﬁnization  to  counting  of
the  gene  and  centromere  signals.  The  data  reported  in  the  current  summary  covers  method  compar-reast cancer
ompanion diagnostic
ison,  assessment  of  staining  quality,  observer-to-observer  reproducibility  as  well  as  reproducibility
within  and  between  laboratories.  Based  on data  from  the  different  studies  it was  concluded  that  HER2
IQFISH  pharmDx  (Dako  Omnis)  is  a reliable  and robust  assay  with  a high  precision  that  is  at least
comparable  to the  manual  HER2  IQFISH  pharmDxTM assay  and  the  PathVysion® HER-2  DNA  Probe
Kit.
©  2016  The  Authors.  Published  by Elsevier  GmbH.  This  is an  open  access  article  under  the  CC  BY. Introduction
Within the last 10–15 years assessment of human epidermal
rowth factor receptor 2 (HER2) status has become increas-
ngly important for treatment of breast cancer. Determination
f HER2 status serves as a critical predictive test for HER2 tar-
eted therapy. The monoclonal antibody trastuzumab (Herceptin®,
oche/Genentech), together with the IHC assay HercepTestTM
Dako Denmark A/S), was the ﬁrst drug-diagnostic combina-
ion to obtain United States Food and Drug Administration
FDA) approval in 1998 [1]. Since then several other drugs
or treatment of HER2-positive breast cancer have been intro-
uced and implemented in the clinic such as the tyrosine kinase
nhibitor lapatinib (Tykerb®/Tyverb®, Novartis), the HER dimer-
zation inhibitor pertuzumab (Perjeta®, Roche/Genentech), and
∗ Corresponding author.
E-mail address: jan.trost@dx-rx.dk (J.T. Jørgensen).
ttp://dx.doi.org/10.1016/j.prp.2016.06.002
344-0338/© 2016 The Authors. Published by Elsevier GmbH. This is an open access articlicense  (http://creativecommons.org/licenses/by/4.0/).
recently the antibody-drug conjugate ado-trastuzumab emtansine
(Kadcyla®, Roche/Genentech) [2–5].
A positive HER2 status is found in approximately 20% of all
women with breast cancer, and assessment of the HER2 status is
currently one of the most frequently performed companion diag-
nostics (CDx) tests in the pathology laboratory [6]. Different slide
based assays are available for assessment of HER2 status in patients
with breast cancer. Overexpression of the HER2 receptor is assessed
by immunohistochemistry (IHC) whereas ampliﬁcation of the HER2
gene is assessed by ﬂuorescence in situ hybridization (FISH) or
other in situ hybridization (ISH) methods. For determination of the
HER2 status in breast cancer the IHC and ISH assays are considered
equally valuable methods [7].
In many laboratories FISH testing is regarded as time-consuming
and technically challenging with an increased risk of human pro-
cessing errors, which calls for automation of the staining procedure
TM[8]. The HER2 IQFISH pharmDx (Dako Omnis) (Dako Denmark
A/S) is a newly developed assay for the automated staining platform
Dako Omnis (Dako Denmark A/S). This assay uses a non-toxic buffer
that signiﬁcantly reduces the hybridization time, which results in
le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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 total turnaround time of 3½ to 4 h from deparafﬁnization to
ounting the gene and centromere signals [9,10]. However, the
ER2 IQFISH pharmDx (Dako Omnis) assay is primarily commer-
ially available in Europe.
For the different HER2 targeted therapies the HER2 assays take
p a critical role in relation to the treatment decision [11]. This posi-
ion requires that the CDx assays have been thoroughly clinically
nd analytically validated and have demonstrated both accuracy
nd precision before they are used for routine analysis in pathology
aboratories. The current article presents a summary of the analyti-
al validation studies that have been conducted with the new HER2
QFISH pharmDx (Dako Omnis) assay in order to fulﬁll the require-
ents for CE marking of In Vitro Diagnostic Medical Devices in the
uropean Union per Directive 98/79/EC.
. Materials and methods
The performance of the HER2 IQFISH pharmDx (Dako Omnis)
ssay using the Dako Omnis staining platform was investigated in
 number of different studies.
.1. Tissue specimens
The breast cancer specimens used in the different studies were
esidual formalin-ﬁxed, parafﬁn-embedded (FFPE) blocks originat-
ng from individual patients. Furthermore, these specimens needed
o fulﬁll the pre-analytical requirements as speciﬁed in the pack-
ge insert for the HER2 IQFISH pharmDx (Dako Omnis) assay, which
eans ﬁxation for 18–24 h using neutral buffered formalin [12].
he specimens were obtained from commercial providers or local
ospitals, and the identity of the patients was not traceable. For
ach of the described studies, tumor specimens were derived from
t least two different hospitals to address the variability in tis-
ue procurement and processing. The specimens were cut in serial
ections of 5 m and mounted on glass slides. For each speci-
en  a pathologist identiﬁed the tumor area, which was indicated
irectly on a hematoxylin and eosin stained slide. The tumor speci-
ens represented a wide range of HER2/CEN-17 ratios representing
oth ampliﬁed and non-ampliﬁed cases. The studies were con-
ucted in accordance with the current version of the World Medical
ssociation Declaration of Helsinki. In the United States the inter-
aboratory reproducibility protocol was reviewed and approved
y an Institutional Review Board (Western International Review
oard, Puyallup, WA). In Europe the study protocols were not sub-
itted to Ethics Committees (EC) as this type of analytical study is
xempt from EC approval.
.2. Dako Omnis
The Dako Omnis instrument is a fully automated staining plat-
orm, which manages the slide staining processes of FFPE specimen
ections for both IHC and ISH independently. The staining process
equires no manual user interaction from loading the FFPE slides to
nloading the stained slides, minimizing human error. The instru-
ent supports continuous loading and unloading of slide racks
nd can run different staining protocols for individual slides at the
ame time, including simultaneous staining of IHC and ISH slides.
he turn-around-time for IHC slides is approximately 2.5 h, and for
SH it is 3½ to 4 h. The instrument uses Dako Omnis ready-to-use
RTU) antibodies and Dako Omnis RTU reagents for the automated
taining processes; however, it can also run customized staining
rotocols if necessary. The instrument is operated by the user from
 touch screen interface [13].d Practice 212 (2016) 735–742
2.3. HER2 IQFISH pharmDx
The HER2 IQFISH pharmDxTM assay for manual staining con-
tains all key reagents required to complete a FISH procedure for
sectioned FFPE specimens. Brieﬂy, the specimen sections were
exposed to heat pre-treatment using a microwave oven and pepsin
digestion at 37 ◦C to prepare the tissue for probe hybridiza-
tion. Denaturation was  performed for 10 min at 66 ◦C followed
by hybridization at 45 ◦C for 90 min  using a Hybridizer (Dako
Denmark A/S). The hybridization was performed using the RTU
FISH Probe Mix  based on a combination of a Texas Red-labeled
DNA probe (HER2) and a ﬂuorescein-labeled PNA probe (CEN-17).
The specimen sections were subjected to stringent wash at 63 ◦C
for 10 min  before dehydration and drying. The dried slides were
subsequently mounted using Fluorescence Mounting Medium con-
taining 4′,6-diamidino-2-phenylindole (DAPI) and cover slipped.
The HER2 IQFISH pharmDx stained slides were evaluated and enu-
merated using a ﬂuorescence microscope with 20×,  40× and 100×
objectives and equipped with appropriate ﬂuorescence ﬁlters for
detection of the DNA and PNA probe signals. The HER2/CEN-17
ratio was calculated based on the enumeration of 20 nuclei from
the invasive tumor area. Based on the ratio, the specimens were
categorized into ampliﬁed (HER2/CEN-17 ≥ 2.0) or non-ampliﬁed
(HER2/CEN-17 < 2.0) categories. Specimens with a ratio between
1.8 and 2.2 (borderline cases) were subjected to enumeration of
20 additional nuclei, and the ratio was then recalculated for the
40 nuclei to determine if ampliﬁcation was present or not. Nor-
mal  cells within the specimens served as an internal control for the
staining [14]. The interpretation of the assay results was  performed
in accordance with the US FDA approved package inserts for HER2
FISH Tests [14,15].
2.4. HER2 IQFISH pharmDx (Dako Omnis)
The HER2 IQFISH pharmDx (Dako Omnis) assay is an assay sim-
ilar to the manual HER2 IQFISH pharmDx assay with the same DNA
(HER2) and PNA (CEN-17) probes; however, it is developed speciﬁ-
cally to run on the automated Dako Omnis staining platform. After
staining on the Dako Omnis platform, the specimen sections were
mounted with Fluorescence Mounting Medium containing DAPI
and coverslipped. The stained slides were evaluated as described
above for the manual HER2 IQFISH pharmDx assay [12].
2.5. Method Comparison – HER2 IQFISH pharmDx versus HER2
IQFISH pharmDx (Dako Omnis)
In order to compare the manual HER2 IQFISH pharmDx assay
with the HER2 IQFISH pharmDx (Dako Omnis) assay for automated
staining, a method comparison study was performed. In this study
the concordance between the two  assays with regards to the HER2
gene status (ampliﬁed/non-ampliﬁed) as well as HER2/CEN-17 ratio
was investigated. The study was  designed as a blinded head-to-
head comparison between the manual and the automated assay.
A total of 140 FFPE breast cancer specimens were included in the
study, which covered the full range of non-ampliﬁed, ‘extended
borderline’ (ratios between 1.5 and 2.5) and ampliﬁed cases. Fur-
thermore, the IHC categories of the included specimens were
known, and in the study protocol it was pre-speciﬁed that at
least 30% should represent the IHC 2+ category. The slides were
stained according to the working procedures for the two  assays,
as described above [12,14]. The evaluation and enumeration of
the manual and automated stained slides were performed by one
blinded certiﬁed observer. Based on the HER2 gene status obtained
for the two assays, the overall percent agreement (OPA), positive
percent agreement (PPA), and negative percent agreement (NPA)
were calculated. Furthermore, the means and the 95% conﬁdence
rch an
i
t
r
c
e
c
2
v
P
s
e
b
s
m
a
t
i
w
v
s
w
a
2
t
(
e
o
s
c
a
s
a
w
e
a
n
3
f
2
(
s
I
c
m
s
o
H
i
2
p
r
i
i
sG. Viale et al. / Pathology – Resea
ntervals (CI) were calculated for the HER2/CEN-17 ratios for the
wo assays. A weighted linear regression plot of the HER2/CEN-17
atios for the two assays was made, and the squared correlation
oefﬁcient (R2) was calculated. The 95% CI for the mean differ-
nce between the two assays at cut-off (HER2/CEN-17 = 2) was  also
alculated.
.6. Method Comparison – HER2 IQFISH pharmDx (Dako Omnis)
ersus PathVysion HER-2 DNA Probe Kit
A method comparison study was likewise performed with
athVysion® HER-2 DNA Probe Kit (Abbott Molecular Inc.) [15],
imilar to the one described above for the two Dako assays. The
valuation and enumeration of the stained slides were performed
y the same certiﬁed observer who performed the scoring of the
lides in the study that compered the manual HER2 IQFISH phar-
Dx  assay with the HER2 IQFISH pharmDx (Dako Omnis) assay for
utomated staining. This study was conducted in order to compare
he HER2 IQFISH pharmDx (Dako Omnis) assay with the PathVys-
on HER-2 DNA Probe Kit. The staining of the breast cancer sections
ith the PathVysion HER-2 DNA Probe Kit was  performed using a
alidated procedure previously used in another method compari-
on study [16]. The statistical evaluation of the data from this study
as similar to the one performed for the comparison of the manual
nd the automated HER2 IQFISH pharmDx assays.
.7. Staining quality
The slides stained in the method comparison study with either
he manual HER2 IQFISH pharmDx assay, the HER2 IQFISH pharmDx
Dako Omnis) assay or the PathVysion HER-2 DNA Probe Kit were
valuated with respect to staining quality based on an assessment
f the signal intensity grade and morphology. For the signal inten-
ity grade, the gene signal (Texas Red/Spectrum Orange) and the
entromere signal (ﬂuorescein/Spectrum Green) were scored using
 0–3 categorical scale with increments of 0.5. The extremes on the
cale were “signals cannot be distinguished” (score 0) and “signals
re clear and distinguishable” (score 3). Similarly, the morphology
as scored using a 0–3 categorical scale with increments of 0.5. The
xtremes on this scale were “tissue structures and nuclear bound-
ries are completely destroyed” (score 0) and “tissue structures and
uclear boundaries are preserved and can be clearly seen” (score
). Descriptive statistics such as mean and 95% CI were calculated
or the different staining quality scores.
.8. Reproducibility – inter-observer
The inter-observer reproducibility for HER2 IQFISH pharmDx
Dako Omnis) was investigated as part of the method comparison
tudy. The same 140 breast cancer specimens, stained with HER2
QFISH pharmDx (Dako Omnis), were evaluated by three blinded
ertiﬁed observers independently of each other. The overall agree-
ent with the median was calculated based on the HER2 gene
tatus for the three observers. Furthermore, the total coefﬁcient
f variation (CV) was calculated based on the Box-Cox transformed
ER2/CEN-17 ratios. Box-Cox data transformation was performed
n order to obtain data variance homogeneity.
.9. Reproducibility – intra-laboratory
The day-to-day and lot-to-lot reproducibility of the HER2 IQFISH
harmDx (Dako Omnis) assay were investigated in a blinded
andomized intra-laboratory study. Eight FFPE breast cancer spec-
mens with different levels of HER2 gene ampliﬁcation were
ncluded in the study. The specimen selection criteria for inclu-
ion in the study were based on either predetermined HER2 IHCd Practice 212 (2016) 735–742 737
scores using the HercepTest assay (Dako Denmark A/S), or the
HER2/CEN-17 ratio using the manual HER2 IQFISH pharmDx assay.
Each specimen was  stained with three different lots of the HER2
IQFISH pharmDx (Dako Omnis) assay on ﬁve non-consecutive days.
A total of 240 specimen sections were processed for the entire
study. Each specimen was stained with the HER2 IQFISH pharmDx
(Dako Omnis) assay 30 times (5 days × 3 lots × 2 duplicates). The
stained sections were evaluated by one blinded certiﬁed observer.
The overall agreement with the median was  calculated as well as
the total CVs for the lot-to-lot and the day-to-day reproducibility.
The calculation of the different CVs was based on Box-Cox trans-
formed data.
2.10. Reproducibility – inter-laboratories
The inter-laboratory and day-to-day reproducibility of the HER2
IQFISH pharmDx (Dako Omnis) assay were investigated in a three-
site multicentre study (two laboratories in Europe and one in the
USA). The study was  designed as a stratiﬁed and blinded study on
consecutive specimen sections from 11 different FFPE breast can-
cer specimens. The specimens in the study were selected based on
their predetermined HER2 IHC score using the HercepTest assay,
or the HER2/CEN-17 ratio using the manual HER2 IQFISH pharmDx
assay. Each specimen was  stained a minimum of ﬁve times on ﬁve
non-consecutive days and scored by one blinded certiﬁed observer
at each of the three laboratories. A total of 192 sections were stained
and included in the statistical analysis. Based on the HER2/CEN-17
ratios obtained at the three laboratories, the total CV was calcu-
lated based on the Box-Cox transformed data and reported with
95% CI. Furthermore, the overall agreement with the median was
calculated.
2.11. Statistical analysis
The statistical analysis described for the individual studies was
conducted using the JMP® software from SAS and/or Excel from
Microsoft.
3. Results
3.1. Method comparison – HER2 IQFISH pharmDx versus HER2
IQFISH pharmDx (Dako Omnis)
The method comparison study between the manual and auto-
mated HER2 IQFISH pharmDx assays included 140 representative
breast cancer specimens. Table 1 shows the distribution of the spec-
imens based on the IHC scoring categories and corresponding HER2
gene status obtained with the manual HER2 IQFISH pharmDx assay.
The study specimens represented all the IHC scoring categories (0;
1+; 2+; 3+) as well as HER2/CEN-17 ‘extended borderline’ cases.
A relatively large proportion of the specimens were either IHC 2+
(38%) and/or HER2/CEN-17 ratio ‘extended borderline’ cases (14%).
The cross tabulation of the HER2 ampliﬁcation status obtained by
the two  assays is shown in Table 2. A perfect concordance between
the two assays was  observed with an OPA of 100%. Both the PPA
and NPA were likewise 100%. The mean HER2/CEN-17 ratios for
the two  assays for all 140 specimens were close to each other.
For the manual HER2 IQFISH pharmDx assay the mean and 95%
CI were 3.75 [3.12; 4.39] and for the HER2 IQFISH pharmDx (Dako
Omnis) assay the corresponding ﬁgures were 3.67 [3.07; 4.26]. A
high degree of correlation, with regards to the HER2/CEN-17 ratios,
was shown between the HER2 IQFISH pharmDx (Dako Omnis) assay
and the manual HER2 IQFISH pharmDx assay (R2 = 0.97; p < 0.0001).
The result of the weighted linear regression plot is shown in Fig. 1.
The 95% CI for the mean difference between the two assays at the
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Table 1
Distribution of the specimens based on the HER2 IHC scoring categories and the corresponding HER2 gene status obtained with the manual HER2 IQFISH pharmDx assay. A
total  of 140 breast cancer specimens were included in the method comparison study between the manual and automated HER2 IQFISH pharmDx assays (N = 140).
HER2 IHC staining score 0 1+ 2+ 3+ Total
N  27 11 53 49 140
HER2 FISH status
Ampliﬁed 2 0 13 48 63
Non-ampliﬁed 25 11 40 1 77
Total  FISH-tested samples 27 11 53 49 140
Table 2
Cross tabulation of the HER2 gene status obtained by the manual HER2 IQFISH pharmDx and the HER2 IQFISH pharmDx (Dako Omnis) assays (N = 140).
HER2 gene status (manual) Total
Non-ampliﬁed Ampliﬁed
HER2 gene status (Dako Omnis) Non-ampliﬁed 77 0 77
Ampliﬁed 0 63 63
Total  77 63 140
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3ig. 1. Correlation between HER2/CEN-17 ratios for the HER2 FISH pharmDx (Dako
mnis) assay and the manual HER2 IQFISH pharmDx assay on 140 breast cancer
pecimens (R2 = 0.97).
ut-off (HER2/CEN-17 = 2) was found to be [0.002; 0.031], which
ndicates that a difference higher than 3% is not expected.
.2. Method comparison – HER2 IQFISH pharmDx (Dako Omnis)
ersus PathVysion HER-2 DNA probe kit
The method comparison study between the HER2 IQFISH phar-
Dx  (Dako Omnis) assay and the PathVysion HER-2 DNA Probe
it included likewise 140 representative breast cancer specimens.
able 3 shows the distribution of the specimens based on the IHC
coring categories and corresponding HER2 gene status obtained
ith the manual HER2 IQFISH pharmDx assay. The study speci-
ens represented all the IHC scoring categories (0; 1+; 2+; 3+)
s well as HER2/CEN-17 ‘extended borderline’ cases. A relatively
arge proportion of the specimens were either IHC 2+ (39%) and/or
ER2/CEN-17 ratio ‘extended borderline’ cases (14%). The cross tab-
lation of the HER2 ampliﬁcation status obtained by the two assays
s shown in Table 4. Also for this comparison a perfect concordance
etween the two assays was observed for all specimens resulting
n an OPA of 100%. Both the PPA and NPA were likewise 100%. The
ean HER2/CEN-17 ratios for the two assays for all 140 specimens
ere very close to each other. For the HER2 IQFISH pharmDx (Dako
mnis) assay the mean and 95% CI were 3.63 [3.02; 4.23] and for the
athVysion HER-2 DNA Probe Kit the corresponding ﬁgures were
.65 [3.05; 4.26]. A high degree of correlation, with regards to theFig. 2. Correlation between HER2/CEN-17 ratios for the HER2 FISH pharmDx (Dako
Omnis) assay and the PathVysion HER-2 Probe Kit on 140 breast cancer specimens
(R2 = 0.96).
HER2/CEN-17 ratios, was  shown between the HER2 IQFISH phar-
mDx  (Dako Omnis) assay and the PathVysion HER-2 DNA Probe Kit
(R2 = 0.96; p < 0.0001). The result of the weighted linear regression
plot is shown in Fig. 2. The 95% CI for the mean difference between
the two  assays at the cut-off (HER2/CEN-17 = 2) was found to be
[0.001; 0.031], which indicates that a difference higher than 3% is
not expected.
3.3. Staining quality
In the method comparison studies 131 specimen sections were
stained with all three assays; the manual HER2 IQFISH pharmDx
assay, the HER2 IQFISH pharmDx (Dako Omnis) assay, and the
PathVysion HER-2 DNA Probe Kit. Each of these 393 specimen sec-
tions was evaluated with respect to staining quality. Both the signal
intensity grade for the gene and the centromere as well as the mor-
phology were evaluated by one blinded certiﬁed observer. The two
HER2 IQFISH pharmDx assays showed very little background stain-
ing, and both the gene and the centromere signals were found to
be bright and punctuate or as clusters in the nuclei of the tumor
cells. Somewhat more background staining was  observed with the
PathVysion HER-2 DNA Probe Kit; however, this background stain-
ing did not signiﬁcantly impact the ability to score the individual
slides. Table 5 provides the mean staining quality scores and 95%
CI for all three HER2 assays. Examples of staining with the manual
G. Viale et al. / Pathology – Research and Practice 212 (2016) 735–742 739
Table  3
Distribution of the specimens based on the HER2 IHC scoring categories and the corresponding HER2 gene status obtained with the manual HER2 IQFISH pharmDx assay. A
total  of 140 breast cancer specimens were included in the method comparison study between the HER2 IQFISH pharmDx (Dako Omnis) assay and the PathVysion HER-2 DNA
Probe  Kit.
HER2 IHC staining score 0 1+ 2+ 3+ Total
N  28 10 54 48 140
HER2 FISH status
Ampliﬁed 1 0 12 47 60
Non-ampliﬁed 27 10 42 1 80
Total  FISH-tested samples 28 10 54 48 140
Table 4
Cross tabulation of the HER2 gene status obtained by the HER2 IQFISH pharmDx (Dako Omnis) assay and the PathVysion HER-2 DNA Probe Kit (N = 140).
HER2 gene status (PathVysion) Total
Non-ampliﬁed Ampliﬁed
HER2 gene status (Dako Omnis) Non-ampliﬁed 80 0 80
Ampliﬁed 0 60 60
Total  80 60 140
Table 5
Staining quality scores for the manual HER2 IQFISH pharmDx assay, the HER2 IQFISH pharmDx (Dako Omnis) assay, and the PathVysion HER-2 DNA Probe Kit (N = 131).
Mean [95% CI] HER2 IQFISH pharmDx HER2 IQFISH pharmDx (Dako Omnis) PathVysion HER-2 DNA Probe Kit
 [2.51
 [2.51
 [2.35
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tHER2 Signal 2.61 [2.56–2.66] 2.56
CEN-17  Signal 2.63 [2.59–2.68] 2.55
Morphology 2.36 [2.32–2.40] 2.39
ER2 IQFISH pharmDx assay and the HER2 IQFISH pharmDx (Dako
mnis) assay are shown in Fig. 3.
.4. Reproducibility – inter-observer
The 140 breast cancer specimen sections stained with the HER2
QFISH pharmDx (Dako Omnis) assay in the method comparison
tudy were also used for an inter-observer reproducibility study.
ll slides were evaluated by three blinded independent certiﬁed
bservers. Based on the HER2 gene status, the agreement between
he three observers was calculated. For 4 out of 140 specimens,
isagreements were observed with regard to the HER2 gene status,
hich resulted in an overall agreement with the median of 98.8%.
he total CV and 95% CI for the inter-observer reproducibility was
ound to be 8.4% [7.5; 9.3].
.5. Reproducibility – intra-Laboratory
Based on 240 stained specimen sections, the lot-to-lot and day-
o-day reproducibility were evaluated. Fig. 4 shows the variation
n the HER2/CEN-17 ratios obtained in the study for the three dif-
erent lots of the HER2 FISH pharmDx (Dako Omnis) assay used for
esting on the ﬁve non-consecutive days. The overall agreement
n the study was calculated to be 97.1%. The total CV and 95% CI
n the study was 4.3% [3.7; 4.9]. Furthermore, a variance compo-
ent analysis showed that the day-to-day and lot-to-lot variations
ccounted for 1.5% and 0.0%, respectively.
.6. Reproducibility – inter-laboratory
In the inter-laboratory and day-to-day reproducibility study the
hree participating laboratories stained and evaluated 11 different
FPE breast cancer specimens, which represented all the IHC scor-
ng categories (0; 1+; 2+; 3+) as well as HER2/CEN-17 ‘extended
orderline’ cases. Each specimen was stained and evaluated a min-
mum of ﬁve times at each laboratory. A total of 192 sections were
tained and included in the statistical analysis. In order to illus-
rate the inter-laboratory and day-to-day variability, the individual–2.61] 2.46 [2.39–2.52]
–2.59] 2.31 [2.25–2.37]
–2.42] 2.24 [2.20–2.28]
HER2/CEN-17 ratios were plotted in a variability gauge chart. Fig. 5
shows that the variance for the individual specimens increased
with increasing HER2/CEN-17 ratios, which illustrates the need for
data transformation to obtain variance homogeneity before calcu-
lation of the CV. The total CV and 95% CI based on the Box-Cox
transformed data was 11.6% [7.9; 15.3]. A variance component
analysis showed that 23% of the total variance comes from the
laboratories, and the remaining 77% is residual variation which cor-
responds to biological variation between the specimen sections and
repeatability factors. The overall agreement in this study was 96.4%.
4. Discussion
The HER2 IQFISH pharmDx assay for manual staining has been
available for clinical use for several years and has shown to be a reli-
able method for assessment of the HER2 gene status [9,10,17,18].
In a number of different validation studies we  have evaluated HER2
IQFISH pharmDx (Dako Omnis), a newly developed assay for the
automated staining platform Dako Omnis, in order to secure reli-
able and robust performance. One aspect of this validation was to
compare the new assay with one or more already validated and reg-
ulatory approved FISH assays. For the HER2 IQFISH pharmDx (Dako
Omnis) assay, method comparison studies were performed with
both the manual HER2 IQFISH pharmDx assay and the PathVysion
HER-2 DNA Probe Kit. For both of these assays a perfect concordance
with the HER2 IQFISH pharmDx (Dako Omnis) assay was demon-
strated. For the HER2 gene status the OPA, PPA and NPA was 100%.
When a weighted linear regression analysis of the HER2/CEN-17
ratios between the HER2 IQFISH pharmDx (Dako Omnis) assay and
the PathVysion HER-2 DNA Probe Kit was performed, the correla-
tion was close to perfect (R = 0.98). The situation was  similar for the
two Dako assays; here also a close to perfect correlation was found
(R = 0.99). Based on the results from these two  studies it was  con-
cluded that the performance of the HER2 IQFISH pharmDx (Dako
Omnis) assay, with regard to the HER2 gene status, was very close
to being identical to the manual HER2 IQFISH pharmDx assay and
the PathVysion HER-2 DNA Probe Kit. The results obtained here
with regards to method comparison are similar to what have been
740 G. Viale et al. / Pathology – Research and Practice 212 (2016) 735–742
Fig. 3. Examples of the same breast cancer specimen sections stained with the manual HER2 IQFISH pharmDx assay (A, B, E, F) or the HER2 IQFISH pharmDx (Dako Omnis)
assay  (C, D, G, H). For the images in the left column (A, C, E, G) a double ﬁlter was  used, and for the images i in the right column (B, D, F, H) a triple ﬁlter was used. Both HER2
non-ampliﬁed cases (A–D) as well as ampliﬁed cases (E–H) are shown.
Fig. 4. Variability gauge charts with the HER2/CEN-17 ratios obtained in the intra-laboratory reproducibility study with 3 different lots of the HER2 FISH pharmDx (Dako
Omnis)  assay tested on 5 non-consecutive days using 8 different breast cancer specimens.
G. Viale et al. / Pathology – Research and Practice 212 (2016) 735–742 741
F t canc
w
s
t
t
w
i
a
s
c
i
D
t
t
f
a
i
s
i
P
q
O
s
s
O
t
t
i
a
a
d
a
C
i
0
l
r
t
v
s
O
aig. 5. Variability gauge charts for the HER2/CEN-17 ratios from each of the 11 breas
ith  the HER2 FISH pharmDx (Dako Omnis) assay.
hown in other studies that have compared automated HER2 FISH
o manual HER2 FISH [19,20].
An important factor to consider when comparing FISH assays is
he quality of the stained slides. The 131 specimen sections that
ere stained with all three assays in the method comparison stud-
es were evaluated with regard to staining quality. The two  Dako
ssays showed similar performance with very little background
taining and bright and distinguishable signals for both gene and
entromere. Also, the evaluation of the morphology resulted in sim-
lar quality scores for these two assays. For the PathVysion HER-2
NA Probe Kit the quality score for the gene signal was similar to
he Dako assays. However, with regard to the centromere signal and
he morphology, a trend towards lower quality scores was  observed
or the PathVysion HER-2 DNA Probe Kit compared with the Dako
ssays, which might be due to the slightly higher background stain-
ng. Overall, it could be concluded that the staining quality of the
lides stained with the HER2 IQFISH pharmDx (Dako Omnis) assay
s similar to the manual Dako assay and at least comparable to the
athVysion HER-2 DNA Probe Kit. The ﬁndings with regard to the
uality of the slides stained with the HER2 IQFISH pharmDx (Dako
mnis) are in agreement with another study that evaluated the
taining quality of the assay [17].
In order to evaluate the inter-observer reproducibility, the 140
pecimen sections stained with the HER2 IQFISH pharmDx (Dako
mnis) assay in the method comparison study were evaluated by
hree blinded independent observers. The overall agreement for
he three observers based on the 420 readings was 98.8%, which
s regarded as excellent. The total CV was found to be 8.4% with
n upper CI limit of 9.3%, which is substantially below the study
cceptance criteria of 25.0%. Likewise, the separate study on the
ay-to-day and the lot-to-lot reproducibility showed an overall
greement of 97.1% and a total CV as low as 4.3%. When the total
V was broken down in day-to-day and lot-to-lot reproducibility,
t was shown that these two variables only accounted for 1.5% and
.0% of the total variance, respectively. The remaining variance was
argely related to repeatability and biological variation. It was quite
emarkable that the lot-to-lot variance in this study did not con-
ribute to the total CV, which indicates a very low and negligible
ariation between the individually produced lots. Based on this
tudy, it can be concluded that the HER2 IQFISH pharmDx (Dako
mnis) assay has a high reproducibility with very low day-to-day
nd lot-to-lot variation.er specimens for the three laboratories in the inter-laboratory reproducibility study
Inter-laboratory and day-to-day reproducibility were evaluated
in a multi-site study using one laboratory in the United States and
two in Europe. The overall agreement in this study was estimated
to be 96.4%, which was  at the same level as seen in the other
reproducibility studies reported here for the HER2 IQFISH phar-
mDx  (Dako Omnis) assay. The total CV for the study was 11.6% with
an upper CI limit of 15.3%, which again was  well below the study
acceptance criteria of 25.0%. Only one disagreement with regards
to the HER2 gene status was  observed between the 3 study sites.
This specimen (ID 68122) was  a ‘true borderline’ case (HER2/CEN-
17 ratio 1.8–2.2), which was  evaluated as ampliﬁed by two of the
study sites and non-ampliﬁed by the third. The increased intra-
observer variation seen with increased HER2/CEN-17 ratios was
also observed in the intra-laboratory reproducibility study and has
previously been described for HER2 FISH testing in breast cancer
[21].
It is important that assay procedures are standardized and one
way to achieve this is through automation. In the 2007 ASCO/CAP
guideline for HER2 testing in breast cancer it was stated that an
optimal assay performance was  more easily obtained using auto-
mated staining platforms rather than manual methods [22]. Beside
advantages in relation to standardization and assay performance it
has also been proposed that automation could result in a more rapid
processing of samples, fewer laboratory errors as well as decrease
personnel and operating costs [20].
In conclusion, the different validation studies summarized in
this article have shown that the performance of the automated
HER2 IQFISH pharmDx (Dako Omnis) assay is at least compara-
ble to the manual HER2 IQFISH pharmDx assay and the PathVysion
HER-2 DNA Probe Kit. Furthermore, the assay has demonstrated
excellent precision which will contribute to more consistent and
standardized HER2 FISH staining of FFPE breast cancer specimens.
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